Table 1.
Patient characteristics
| Liver recurrence | Extrahepatic recurrence | 5-year no evidence of disease (NED) | Total | ||
|---|---|---|---|---|---|
| (n = 40) | (n = 40) | (n = 40) | (n = 120) | p | |
| Gender | |||||
| Male | 18 (45%) | 17 (43%) | 19 (48%) | 54 (45%) | 0.904 |
| Female | 22 (55%) | 23 (58%) | 21 (53%) | 66 (55%) | |
| Median age at diagnosis, yr (range) | 65.5 (37.0 – 91.0) | 64.1 (37.0 – 90.0) | 59.0 (29.0 – 80.0) | 62.5 (29.0 – 91.0) | 0.039 |
| Median BMI, kg/m2 (range) | 26.3 (20.2 – 43.9) | 26.0 (18.7 – 37.7) | 28.6 (16.2 – 52.4) | 26.9 (16.2 – 52.4) | 0.247 |
| Location of primary | |||||
| Right | 17 (43%) | 19 (48%) | 23 (58%) | 57 (48%) | 0.393 |
| Left | 23 (58%) | 21 (53%) | 17 (43%) | 63 (53%) | |
| Previous cancer | |||||
| No | 33 (83%) | 28 (70%) | 31 (78%) | 92 (77%) | 0.413 |
| Yes | 7 (18%) | 12 (30%) | 9 (23%) | 28 (23%) | |
| Previous chemotherapy | |||||
| No | 38 (95%) | 38 (95%) | 37 (93%) | 113 (94%) | 0.859 |
| Yes | 2 (5%) | 2 (5%) | 3 (8%) | 7 (6%) | |
| Preoperative CEA, median (range) | 4.15 (0.80 – 201.00) | 5.00 (0.70 – 29.300) | 3.00 (0.60 – 19.50) | 3.90 (0.60 – 201.00) | 0.478 |
| Smoking status | |||||
| Never smoker | 23 (58%) | 22 (55%) | 23 (58%) | 68 (57%) | 0.801 |
| Former smoker | 15 (38%) | 14 (35%) | 12 (30%) | 41 (34%) | |
| Current smoker | 2 (5%) | 4 (10%) | 5 (13%) | 11 (9%) | |
| T stage | |||||
| T1 | 2 (5%) | 1 (3%) | 2 (5%) | 5 (4%) | 0.449 |
| T2 | 1 (3%) | 2 (5%) | 0 (0%) | 3 (3%) | |
| T3 | 30 (75%) | 25 (63%) | 32 (80%) | 87 (73%) | |
| T4 | 7 (18%) | 12 (30%) | 6 (15%) | 25 (21%) | |
| Lymph node stage | |||||
| No | 20 (50%) | 20 (50%) | 20 (50%) | 60 (50%) | 0.912 |
| N1 | 12 (30%) | 11 (28%) | 14 (35%) | 37 (31%) | |
| N2 | 8 (20%) | 9 (23%) | 6 (15%) | 23 (19%) | |
| TNM stage | |||||
| Stage II | 20 (50%) | 20 (50%) | 20 (50%) | 60 (50%) | 1.000 |
| Stage III | 20 (50%) | 20 (50%) | 20 (50%) | 60 (50%) | |
| Grade | |||||
| Moderately differentiated | 34 (85%) | 31 (78%) | 30 (75%) | 95 (79%) | 0.518 |
| Poorly differentiated | 6 (15%) | 9 (23%) | 10 (25%) | 25 (21%) | |
| Lymphovascular invasion | |||||
| No | 18 (45%) | 19 (48%) | 20 (50%) | 57 (48%) | 0.905 |
| Yes | 22 (55%) | 21 (53%) | 20 (50%) | 63 (53%) | |
| Perineural invasion | |||||
| No | 28 (70%) | 24 (60%) | 33 (83%) | 85 (71%) | 0.177 |
| Yes | 12 (30%) | 15 (38%) | 7 (18%) | 34 (28%) | |
| Unknown | 0 (0%) | 1 (3%) | 0 (0%) | 1 (1%) | |
| Adjuvant chemotherapy | |||||
| No | 19 (48%) | 16 (40%) | 12 (30%) | 47 (39%) | 0.274 |
| Yes | 21 (53%) | 24 (60%) | 28 (70%) | 73 (61%) |